Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO ...

Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than ...

The results for Lunsumio, also known as mosunetuzumab, and Polivy, also known as polatuzumab vedotin, came as part of a phase 3 study. Roche said it would now submit results to global health ...

Genentech, part of the Roche Group (OTCQX:RHHBY), said that a late-stage study testing Lunsumio, along with Polivy, showed ...

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...

In this video, Ian W. Flinn, MD, PhD, discusses the phase 2 MorningSun study evaluating fixed-duration subcutaneous mosunetuzumab in patients with previously untreated, high-tumor burden follicular ...

Data presented at EHA 2025 demonstrated that the Epkinly / R-ICE combination produced an 87% ORR in transplant-eligible r/r ...

Its effectiveness in both treatment-naïve and relapsed patients has reinforced its central role in clinical practice. LUNSUMIO (mosunetuzumab) is a bispecific antibody therapy designed to treat adults ...

The European Commission has approved mosunetuzumab under the Lunsumio trade name for relapsed or refractory FL, the most common slow-growing form of non-Hodgkin lymphoma (NHL), after two or more ...